Wearable Optical Monitoring of Brain Function in Healthy Adults and People With Dementia

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Dementia is associated with a variety of neurovascular and neurometabolic abnormalities. Traditional imaging techniques used to investigate such abnormalities, such as Positron Emission Tomography and functional Magnetic Resonance Imaging, are not always well tolerated, have expensive start up and running costs, and are limited with regards to the types of experiments that can be performed as they can be highly sensitive to movement, are noisy, and have physical restrictions. Near-infrared spectroscopy (NIRS) is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to detect relative changes in concentration of oxygenated and deoxygenated haemoglobin, and the oxidation state of Cytochrome C Oxidase. As such, NIRS can provide measures of brain oxygenation and metabolism. NIRS is less sensitive to movement, is well tolerated and has few contraindications. It is thus a promising candidate for use in clinics or in peoples' homes for monitoring dementia. In the present study, the investigators aim to use both dual-wavelength and broadband NIRS in a range of dementia subtypes, including Alzheimer's Disease and Dementia with Lewy Bodies, and severities, including Mild Cognitive Impairment, to identify how brain oxygenation and metabolism is altered in dementia and across various clinical subgroups. The investigators also aim to determine the relationship between brain oxygenation and metabolism in dementia, and use machine learning approaches to identify optical biomarkers for dementia.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• A diagnosis of probable:

‣ Lewy Body Dementia

⁃ Alzheimer's Disease

⁃ Mild Cognitive Impairment (MCI-LB or MCI-AD) OR

• Cognitively normal for their education and age, with a MMSE score above 26 AND

‣ A good grasp of the English language

⁃ An informant (either a carer or family member) who will be available throughout testing (only relevant if in a patient group)

Locations
Other Locations
United Kingdom
Univeristy of Cambridge
RECRUITING
Cambridge
Contact Information
Primary
Emilia Butters, MSc
eb857@cam.ac.uk
07462064164
Time Frame
Start Date: 2023-05-01
Estimated Completion Date: 2025-09-01
Participants
Target number of participants: 200
Treatments
Dementia with Lewy Bodies
These subjects should meet the criteria for dementia with Lewy Bodies (McKeith et al. (2005). Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology. 65:1863-72.).
Alzheimer's Disease
These subjects should have a clinical diagnosis of AD in accordance with the National Institute of Neurological Disorders and Stroke-Alzheimer Disease and Related Disorders criteria (McKhann, G. M., et al. 2011. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7:263-9.).
Mild Cognitive Impairment - LB
Mild Cognitive Impairment in a single or a multiple domain (Jak et al., 2009) with at least one LB symptom (MCI-LB; McKeith, I. G., et al. 2020. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 94(17): 743-55.).
Mild Cognitive Impairment - AD
Mild Cognitive Impairment in a single or a multiple domain (Jak et al., 2009) with AD symptoms (MCI-AD; Dubois, B., et al. 2009. Early detection of Alzheimer's disease: new diagnostic criteria. Dialogues Clin Neurosci. 11(2): 135-9.).
Healthy controls
These subjects should have MMSE scores above 26, no regular memory complaints, no signs/symptoms of dementia and no unstable or significant medical illness.
Related Therapeutic Areas
Sponsors
Collaborators: The Gianna Angelopoulos Programme for Science, Technology and Innovation, Alzheimer's Research UK, Cambridgeshire and Peterborough NHS Foundation Trust, The Newton Trust
Leads: University of Cambridge

This content was sourced from clinicaltrials.gov